Italia markets closed

Dow Jones
40.022,61
+19,02(+0,05%)
Nasdaq
16.792,60
+106,63(+0,64%)
Nikkei 225
39.069,68
+282,30(+0,73%)
EUR/USD
1,0864
-0,0008(-0,08%)
Bitcoin EUR
62.071,90
+469,07(+0,76%)
CMC Crypto 200
1.373,50
+19,08(+1,41%)

NVCR Jul 2024 22.500 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

3,9000

+1,6500

(+73,33%)

In data: 11:27AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in